Supplementary Information

Unbiased identification of the liposome protein corona using photoaffinity based chemoproteomics

Roy Pattipeiluhu1, Stefan Crielaard1, Iris Klein-Schiphorst1, Bogdan I. Florea2, Alexander Kros1 and Frederick Campbell2

1Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands

2Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
## Contents

Supplementary Figures and Tables .................................................................................. 3

Chemical Synthesis ........................................................................................................ 21
  General ...................................................................................................................... 21
  Procedures ................................................................................................................ 22
    Synthesis of diazirine and diacylglycerol building blocks ........................................... 22
    Phosphoramidite synthesis of IKS ........................................................................... 29

Biological Methods & Proteomics .................................................................................. 32
  General ...................................................................................................................... 32
  Procedures ................................................................................................................ 33
    Liposome preparation ........................................................................................... 33
    Photoaffinity method ........................................................................................... 33
    Protein binding validation experiment .................................................................. 35
    Centrifugation method ........................................................................................ 36
    In-solution reduction, alkylation and digestion ......................................................... 38
    StageTips desalting ............................................................................................... 38
    NanoUPLC-MS/MS analysis ................................................................................ 39
    MS acquisition method ......................................................................................... 40
    Proteomic analysis ................................................................................................ 41

NMR and MS spectra ..................................................................................................... 45
**Supplementary Figures and Tables**

**Figure S1.** Synthesis scheme of the PAL probe IKS02. Reagents and conditions: (a) 1. 7N NH₃ in methanol; 2. NH₂OSO₃H; 3. I₂, Et₃N; 4. TsCl, pyridine, 20% over 4 steps; (b) DMEA, acetone, quant.; (c) AcCl, MeOH, 92%; (d) 1. MsCl, Et₃N, DCM; 2. NaN₃, DMF, 70 °C, 91% over 2 steps; (e) 4M NaOH, dioxane, 95%; (f) 1BDMSCl, imidazole, DCM:DMF (1:1), -18 °C, 34%; (g) Stearic acid, DCC, DMAP, DCM, 76%; (h) 5, DCC, DMAP, DCM, 64%; (i) Et₃N·3HF, THF, quant.; (j) PCI(OCH₂CH₂CN)(NPr₂), Et₃N, DCM, 74%; (k) 1. 2, imidazole, DCM; 2. 1BuOOH, DCM, 10% over 2 steps; (l) 1BuNH₂, DCM, 48%. Detailed procedures are described in the Chemical Synthesis section of the Supplementary Information.
Table S1. Dynamic Light Scattering and zeta potential measurements for the formulations used in this study. All formulations were made through thin film hydration and extrusion described in the Biological Methods & Proteomics section of the Supplementary Information. Liposome composition and size of formulations used in clinic or clinical trials obtained from Ref. 1.
Figure S2. Sedimentation of liposome-protein complexes. (a) Liposomes containing 1 mol% fluorescent lipid (DOPE-LR) were incubated in human serum at a 1:1 ratio, followed by centrifugation for 15 minutes at 17,500 g. The supernatant was removed, the pellet was resuspended in PBS and the centrifugation and wash step repeated twice. After the last removal of the supernatant, the liposome-protein complexes were resolved on SDS-PAGE as shown in Figure S7. (b) Fluorescence measurements of supernatant and pellet from the steps described in a. Pellets were resuspended in PBS. All samples were performed in triplicate. Fluorescence of DOPE-LR (560 ex./583 em.) was determined using a fluorescence plate reader (Tecan M200, Tecan Life Sciences). (c) Dynamic Light Scattering (DLS) size measurements of the extruded liposomes prior to incubation in human serum. (d) DLS size measurements of the liposome-protein pellet after the first centrifugation step. (e) DLS size measurements of the liposome-protein pellet after the final centrifugation step. Pellets were resuspended in PBS (100 µL) for DLS measurements.
Figure S3. In-gel fluorescence and Coomassie stained SDS-PAGE gels for the photoaffinity method, displaying the fluorescently labelled protein corona (in-gel fluorescence) and the total protein content (Coomassie Blue). 10 µg total protein was loaded in each lane, as determined by BCA assay. Gels were run on a 10% polyacrylamide gel as described in the Biological Methods & Proteomics section.
### ISOQuant Configuration

| Parameter                                                      | Value                                                                 |
|----------------------------------------------------------------|----------------------------------------------------------------------|
| isoquant.pluginQueue.name                                      | design project and run ISOQuant analysis                              |
| process.peptide.deplete.PEP_Frag_2                            | false                                                                |
| process.peptide.deplete.CURATED_0                             | false                                                                |
| process.peptide.statistics.doSequenceSearch                    | false                                                                |
| process.emrt.minIntensity                                     | 1000                                                                 |
| process.emrt.minMass                                          | 500                                                                  |
| process.emrt.rt.alignment.match.maxDeltaMass.ppm               | 10                                                                   |
| process.emrt.rt.alignment.match.maxDeltaDriftTime              | 2                                                                   |
| process.emrt.rt.alignment.normalizeReferenceTime               | true                                                                |
| process.emrt.rt.alignment.maxProcesses                         | 24                                                                  |
| process.emrt.rt.alignment.referenceRun.selectionMethod         | AUTO                                                                |
| process.emrt.clustering.preclustering.orderSequence            | MTMTMT                                                              |
| process.emrt.clustering.preclustering.maxDistance.mass.ppm     | 6.06E-6                                                             |
| process.emrt.clustering.preclustering.maxDistance.time.min     | 0.202                                                               |
| process.emrt.clustering.preclustering.maxDistance.drift        | 2.02                                                                |
| process.emrt.clustering.distance.unit.mass.ppm                 | 6.06E-6                                                             |
| process.emrt.clustering.distance.unit.time.min                 | 0.2                                                                 |
| process.emrt.clustering.distance.unit.drift.bin                | 2                                                                   |
| process.emrt.clustering.dbscan.minNeighborCount                | 1                                                                   |
| process.identification.peptide.minReplicationRate              | 2                                                                   |
| process.identification.peptide.minScore                        | 6                                                                   |
| process.identification.peptide.minSequenceLength               | 6                                                                   |
| process.identification.peptide.acceptType.PEP_Frag_1           | true                                                                |
| process.identification.peptide.acceptType.IN_SOURCE            | false                                                               |
| process.identification.peptide.acceptType.MISSING_CLEAVAGE     | false                                                               |
| process.identification.peptide.acceptType.NEUTRAL_LOSS_H2O      | false                                                               |
| process.identification.peptide.acceptType.NEUTRAL_LOSS_NH3      | false                                                               |
| process.identification.peptide.acceptType.PEP_Frag_2            | false                                                               |
| process.identification.peptide.acceptType.DDA                  | true                                                                |
| process.identification.peptide.acceptType.VAR_MOD              | false                                                               |
| process.identification.peptide.acceptType.PTM                  | false                                                               |
| process.annotation.peptide.maxSequencesPerEMRTCluster          | 1                                                                   |
| process.annotation.protein.resolveHomology                      | true                                                                |
| process.annotation.peptide.maxFDR                              | 0.01                                                                |
| process.annotation.useSharedPeptides                           | unique                                                              |
| process.normalization.lowess.bandwidth                         | 0.3                                                                 |
| process.normalization.orderSequence                            | XPIR                                                                |
| process.normalization.minIntensity                             | 3000                                                                |
| process.quantification.peptide.minMaxScorePerCluster           | 0                                                                   |
| process.quantification.peptide.acceptType.IN_SOURCE            | false                                                               |
| process.quantification.peptide.acceptType.MISSING_CLEAVAGE      | false                                                               |
| process.quantification.peptide.acceptType.NEUTRAL_LOSS_H2O      | false                                                               |
| process.quantification.peptide.acceptType.NEUTRAL_LOSS_NH3      | false                                                               |
| process.quantification.peptide.acceptType.PEP_Frag_1            | true                                                                |
| process.quantification.peptide.acceptType.PEP_Frag_2            | false                                                               |
| process.quantification.peptide.acceptType.DDA                  | false                                                               |
| process.quantification.peptide.acceptType.VAR_MOD              | false                                                               |
| process.quantification.peptide.acceptType.PTM                  | true                                                                |
| process.quantification.topx.degree                             | 3                                                                   |
| process.quantification.topx.allowDifferentPeptides             | false                                                               |
| process.quantification.minPeptidesPerProtein                   | 3                                                                   |
| process.quantification.absolute.standard.entry                 | ENO1_YEAST                                                          |
| process.quantification.absolute.standard.fmol                   | 50                                                                  |
| process.quantification.topx.allowDifferentPeptides             | false                                                               |
| process.quantification.topx.absolute.standard.entry            | ENO1_YEAST                                                          |
| process.quantification.topx.absolute.standard.fmol             | 50                                                                  |
| process.quantification.maxProteinFDR                           | 0.01                                                                |

**Table S2.** ISOQuant label-free quantification (LFQ) configuration based on the TOP3 approach.
Figure S4. Abundance profiles for proteins meeting the selection criteria. Displayed as plots, showing the protein entry and abundance in both +UV and -UV samples, as well as in table format.
| Abundance | Protein name                                                      | Protein entry | IEP | MW (kDa) | average ppm |
|-----------|------------------------------------------------------------------|---------------|-----|----------|-------------|
| 1         | Serum albumin                                                    | ALBU          | 5.89| 71.4     | 26.08       |
| 2         | Complement C3                                                   | CO3           | 5.99| 188.7    | 65.56       |
| 3         | Serotransferrin                                                  | TRFE          | 6.78| 79.3     | 29.71       |
| 4         | Alpha-2-macroglobulin                                           | A2MG          | 6.04| 164.7    | 58.25       |
| 5         | Immunoglobulin heavy constant gamma 1                           | IGHG1         | 8.20| 36.6     | 16.61       |
| 6         | Alpha-1-antitrypsin                                             | A1AT          | 5.25| 46.9     | 19.39       |
| 7         | Immunoglobulin heavy constant mu                                | IGHM          | 6.37| 50.1     | 21.16       |
| 8         | Apolipoprotein A-I                                              | APOA1         | 5.44| 30.8     | 14.74       |
| 9         | Immunoglobulin heavy constant gamma 2                           | IGHG2         | 7.45| 36.5     | 17.66       |
| 10        | Vitamin D-binding protein                                       | VTDB          | 5.16| 54.5     | 23.22       |
| 11        | Immunoglobulin heavy constant alpha 1                           | IGHA1         | 6.09| 38.5     | 18.53       |
| 12        | Immunoglobulin kappa constant                                   | IGKC          | 6.13| 11.9     | 10.02       |
| 13        | Complement factor H                                             | CFAH          | 6.21| 143.8    | 54.33       |
| 14        | Inter-alpha-trypsin inhibitor heavy chain H2                    | ITIH2         | 6.43| 106.9    | 42.45       |
| 15        | Apolipoprotein A-IV                                             | APOA4         | 5.12| 45.4     | 21.84       |
| 16        | Complement factor B                                             | CFAB          | 6.69| 86.9     | 36.53       |
| 17        | Haptoglobin                                                     | HPT           | 6.15| 45.9     | 23.01       |
| 18        | Immunoglobulin heavy constant gamma 3                           | IGHG3         | 7.79| 42.3     | 22.70       |
| 19        | Plasminogen                                                     | PLMN          | 6.93| 93.3     | 39.75       |
| 20        | C4b-binding protein alpha                                        | C4BPA         | 7.02| 69.1     | 32.04       |
| 21        | Complement C4-B                                                 | CO4B          | 6.90| 194.3    | 74.06       |
| 22        | Plasma protease C1 inhibitor                                    | C1            | 6.11| 55.4     | 27.83       |
| 23        | Antithrombin-III                                                | ANT3          | 6.33| 53.1     | 27.46       |
| 24        | Beta-2-glycoprotein 1                                            | APOH          | 7.87| 39.6     | 23.83       |
| 25        | Heminopexin                                                     | HEMO          | 6.60| 52.4     | 28.01       |
| 26        | Enolase 1                                                       | ENO1          | 6.19| 46.9     | 26.35       |
| 27        | Immunoglobulin heavy constant gamma 4                           | IGHG4         | 7.13| 36.5     | 23.53       |
| 28        | Inter-alpha-trypsin inhibitor heavy chain H4                    | ITIH4         | 6.56| 103.6    | 46.05       |
| 29        | Complement C5                                                   | C05           | 6.11| 190.0    | 75.04       |
| 30        | Gelatin                                                         | GELS          | 5.87| 86.1     | 40.66       |
| 31        | Alpha-1-antichymotrypsin                                        | AACT          | 5.19| 47.8     | 28.00       |
| 32        | Transthyretin                                                   | TTHY          | 5.42| 16.0     | 17.81       |
| 33        | Apolipoprotein A-II                                             | APOA2         | 6.64| 11.3     | 16.98       |
| 34        | Inter-alpha-trypsin inhibitor heavy chain H1                    | ITIH1         | 6.35| 101.8    | 47.40       |
| 35        | Angiotensinogen                                                 | ANG1T         | 5.88| 53.4     | 31.44       |
| 36        | Complement C1s subcomponent                                     | C1S           | 4.66| 78.2     | 39.63       |
| 37        | Prothrombin                                                    | THRB          | 5.54| 71.5     | 38.02       |
| 38        | Ceruloplasmin                                                   | CERU          | 5.35| 123.1    | 55.47       |
| 39        | Apolipoprotein E                                                | APOE          | 5.49| 36.3     | 26.92       |
| 40        | Heparin cofactor 2                                              | NEF2          | 6.47| 57.2     | 34.57       |
| 41        | Alpha-2-HS-glycoprotein                                         | FETUA         | 5.35| 40.1     | 28.83       |
| 42        | Hemoglobin subunit alpha                                        | HBA           | 9.20| 15.3     | 22.17       |
| 43        | Apolipoprotein C III                                            | APOC3         | 5.06| 10.9     | 19.64       |
| 44        | Hemoglobin subunit beta                                         | HBB           | 6.91| 16.1     | 22.34       |
| 45        | Complement C1r subcomponent                                     | C1R           | 5.80| 81.7     | 44.15       |
| 46        | Complement C1q subcomponent subunit B                           | C1QB          | 8.87| 26.9     | 27.27       |
| 47        | N-acetylmuramoyl-L-alanine amidase                               | PGRP2         | 7.29| 62.8     | 39.03       |
| 48        | Alpha-2-antiplasmin                                             | A2AP          | 5.87| 54.9     | 36.26       |
| 49        | Complement C1q subcomponent subunit C                           | C1QC          | 8.54| 26.0     | 27.85       |
| 50        | Complement C4-A                                                 | CO4A          | 6.68| 194.4    | 83.69       |

**Table S3.** Abundance of proteins in human serum determined with LFQ based on the TOP3 approach, analysed with the ISOQuant software.
|   | Protein Name                  | Gene Symbol | Fold Changes | NTS   | PTAS  |
|---|--------------------------------|-------------|-------------|-------|-------|
| 51 | Histidine-rich glycoprotein   | HRG         | 7.13        | 60.5  | 39.56 |
| 52 | Clusterin                     | CLUS        | 5.87        | 53.1  | 36.98 |
| 53 | Alpha-1B-glycoprotein         | A1BG        | 5.50        | 54.8  | 37.77 |
| 54 | Leucine-rich alpha-2-glycoprotein | A2GL     | 6.53        | 38.4  | 32.98 |
| 55 | Serum amyloid P-component      | SAMP        | 6.13        | 25.5  | 28.88 |
| 56 | Kininogen-1                   | KNG1        | 6.38        | 73.0  | 45.14 |
| 57 | Haptoglobin-related protein    | HPTR        | 6.71        | 39.5  | 34.75 |
| 58 | Coagulation factor XII         | F2A2        | 7.55        | 70.1  | 45.54 |
| 59 | Apolipoprotein C-I             | APOC1       | 9.43        | 9.3   | 26.25 |
| 60 | Corticosteroid-binding globulin | CBG      | 5.61        | 45.3  | 37.31 |
| 61 | Apolipoprotein C-II            | APOC2       | 4.44        | 11.3  | 25.91 |
| 62 | Protein AMBP                   | AMBP        | 5.90        | 39.9  | 36.27 |
| 63 | CDS antigen-like               | CD5L        | 5.15        | 39.6  | 36.26 |
| 64 | Serum paraoxonase/arylesterase 1 | PON1     | 4.93        | 39.9  | 36.61 |
| 65 | Complement component C9        | C9          | 5.28        | 64.7  | 45.31 |
| 66 | Apolipoprotein L1              | APOL1       | 5.49        | 44.0  | 38.84 |
| 67 | Vitronection                   | VTNc        | 5.45        | 55.1  | 42.85 |
| 68 | Vitamin K-dependent protein S  | PROS        | 5.35        | 77.2  | 50.51 |
| 69 | A-1 antigen-like               | AFAM        | 5.55        | 71.0  | 48.85 |
| 70 | Apolipoprotein D               | APOD        | 4.87        | 21.6  | 32.48 |
| 71 | Immunoglobulin J chain         | IGI         | 4.91        | 18.6  | 31.82 |
| 72 | Pigment epithelium-derived factor | PEDF    | 5.97        | 46.5  | 41.82 |
| 73 | Carboxypeptidase B2            | CBP2        | 7.54        | 49.0  | 43.51 |
| 74 | Kallikrein                      | KLK1        | 7.58        | 48.7  | 43.76 |
| 75 | Plasma kallikrein              | KLK3        | 8.10        | 73.5  | 52.53 |
| 76 | Proporatin                     | PROP        | 7.75        | 53.8  | 46.18 |
| 77 | Complement factor I             | C1F1        | 7.31        | 68.1  | 51.15 |
| 78 | Insulin-like growth factor-binding protein complex acid labile subunit | ALS | 6.37 | 66.8 | 50.72 |
| 79 | Carboxypeptidase N subunit 2   | CNP2        | 5.59        | 61.4  | 49.00 |
| 80 | Retinol-binding protein 4      | RET4        | 5.68        | 23.4  | 36.68 |
| 81 | Thyroxine-binding globulin     | THBG        | 5.88        | 46.7  | 44.85 |
| 82 | Apolipoprotein M               | APOM        | 5.63        | 21.6  | 36.74 |
| 83 | Serum amyloid A-4 protein      | SAA4        | 9.41        | 14.9  | 36.09 |
| 84 | Alpha-1-acid glycoprotein 1    | A1AG1       | 4.74        | 23.7  | 37.83 |
| 85 | Alpha-1-acid glycoprotein 2    | A1AG2       | 4.85        | 23.9  | 38.25 |
| 86 | Lumican                        | LUM         | 6.19        | 38.8  | 43.99 |
| 87 | Immunoglobulin heavy constant delta | IGHD | 8.10 | 42.8 | 46.30 |
| 88 | Zinc-alpha-2-glycoprotein      | ZAAG        | 5.66        | 34.5  | 43.05 |
| 89 | Immunoglobulin lambda variable 1-51 | LV151 | 6.86 | 12.5 | 36.45 |
| 90 | Apolipoprotein C-IV            | APOC4       | 9.13        | 14.9  | 38.34 |
| 91 | Torranectin                    | TETN        | 5.38        | 22.9  | 40.11 |
| 92 | Hemoglobin subunit delta       | HB          | 8.23        | 16.2  | 39.13 |

Table S3. Continued.
Figure S5. Competitive binding of human serum albumin (ALBU), transferrin (TRFE) and prothrombin (THRB). Increasing concentrations (1:1 to 1:9 molar ratios) of unlabeled AmBisome liposomes were incubated, together with AmBisome liposomes containing IKS02 (5 mol%), in a predefined mixture of purified human serum proteins (see Figure 4). Captured proteins were separated by SDS-PAGE and visualized by in-gel fluorescence (Cy5). Protein loading determined by Coomassie Blue (coom.).
Figure S6. Validation of apolipoprotein E and A1 binding to Myocet and EndoTAG-1 liposomes. (a) Liposomes, containing 5 mol% IKS02, were incubated in a mixture of purified human serum proteins consisting of apolipoprotein E (APOE, 2 µg/mL), serum albumin (ALBU, 25 µg/mL), apolipoprotein A-I (APOA1, 2 µg/mL), transferrin (TRFE, 10 µg/mL) and prothrombin (THRB, 2 µg/mL). (b,c) Volcano plot of protein enrichment over background (log2(+UV/-UV)) plotted against the statistical significance of this comparison (-log10(p-value)). Proteins meeting all selection criteria labelled in green. For EndoTAG-1, abundance plot of apoE and apoA1 within the +UV samples. (d) Competition assay of apolipoprotein E and A1 binding. Increasing concentrations (1:1 to 1:9 molar ratios) of unlabelled EndoTAG-1 liposomes were incubated, together with EndoTAG-1 liposomes containing IKS02 (5 mol%), in the above predefined mixture of purified human serum proteins. Captured apoE and apoA1 on the
surface of IKS02-labeled EndoTAG-1 liposomes were separated by SDS-PAGE and visualized by in-gel fluorescence (CyS). Protein loading determined by Coomassie Blue (coom.). Protein structures were obtained from the protein data bank (PDB): (APOE: 2L7B, APOA1: 1AV1, ALBU: 1E78, THRB: 6C2W, TRFE: 1D3K). Illustrations were generated using Illustrate.
Figure S7. Gel electrophoresis (SDS-PAGE) of protein coronas isolated via centrifugation, displaying Coomassie Blue stained replicates (n=6) used for in-gel digestion. The total amount of liposome-protein complexes isolated by centrifugation were loaded in each lane without correction. Gels were run on a 10% polyacrylamide gel as described in the Biological Methods & Proteomics section.
Table S4. Protein abundancy for the AmBisome protein corona from the centrifugation method determined with LFQ based on the TOP3 approach, analysed with the ISOQuant software.

| Abundance | Protein name                           | Protein entry | IEP | MW (kDa) | average ppm |
|-----------|----------------------------------------|---------------|-----|----------|-------------|
| 1         | Serum albumin                          | ALBU          | 5.89| 71       | 166624      |
| 2         | Complement C3                          | CO3           | 5.99| 189      | 125283      |
| 3         | Immunoglobulin heavy constant mu       | IGHM          | 6.37| 50       | 42156       |
| 4         | Apolipoprotein E                       | APOE          | 5.49| 36       | 38054       |
| 5         | Serotransferrin                        | TRFE          | 6.78| 79       | 20767       |
| 6         | Alpha-2-macroglobulin                  | A2MG          | 6.04| 165      | 18900       |
| 7         | Immunoglobulin heavy constant alpha 1  | IGHA1         | 6.09| 39       | 11451       |
| 8         | Apolipoprotein A-IV                    | APOA4         | 5.12| 45       | 10705       |
| 9         | Apolipoprotein A-I                     | APOA1         | 5.44| 31       | 9582        |
| 10        | Clusterin                              | CLUS          | 5.87| 53       | 6738        |
| 11        | Haptoglobin                            | HPT           | 6.15| 46       | 6114        |
| 12        | Apolipoprotein D                       | APOD          | 4.87| 22       | 2933        |
| Abundance | Protein name                                      | Protein entry | IEP  | MW (kDa) | average ppm |
|-----------|--------------------------------------------------|---------------|------|----------|-------------|
| 1         | Serum albumin                                    | ALBU          | 5.89 | 71       | 132524      |
| 2         | Complement C3                                    | C3            | 5.99 | 189      | 61074       |
| 3         | Pyruvate carboxylase__ mitochondrial             | PYC           | 6.41 | 130      | 51995       |
| 4         | Vitronectin                                      | VTNC          | 5.45 | 55       | 51013       |
| 5         | Apolipoprotein E                                 | APOE          | 5.49 | 36       | 47754       |
| 6         | Propionyl-CoA carboxylase alpha chain__ mitochondrial | PCCA      | 7.27 | 81       | 45110       |
| 7         | Immunoglobulin heavy constant mu                 | IGHM          | 6.37 | 50       | 43059       |
| 8         | Inter-alpha-trypsin inhibitor heavy chain H1     | ITIH1         | 6.35 | 102      | 31785       |
| 9         | Inter-alpha-trypsin inhibitor heavy chain H2     | ITIH2         | 6.43 | 107      | 29841       |
| 10        | Prothrombin                                      | THRBP         | 5.54 | 72       | 28366       |
| 11        | Alpha-2-macroglobulin                            | A2MG          | 6.04 | 165      | 17305       |
| 12        | Serotransferrin                                  | TRFE          | 6.78 | 79       | 16843       |
| 13        | Apolipoprotein A-IV                              | APOA4         | 5.12 | 45       | 14697       |
| 14        | Clusterin                                        | CLUS          | 5.87 | 53       | 11392       |
| 15        | Immunoglobulin heavy constant alpha 1            | IGH1A         | 6.09 | 39       | 10089       |
| 16        | Alpha-1-antitrypsin                              | A1AT          | 5.25 | 47       | 9162        |
| 17        | Haptoglobin                                      | HPT           | 6.15 | 46       | 7963        |
| 18        | Serum paraoxonase/arylesterase 1                 | PON1          | 4.93 | 40       | 7590        |
| 19        | Apolipoprotein A-I                               | APOA1         | 5.44 | 31       | 7056        |
| 20        | Hyaluronan-binding protein 2                      | HABP2         | 6.11 | 65       | 5028        |
| 21        | Apolipoprotein C-II                              | APOC2         | 4.44 | 11       | 4953        |
| 22        | Heparin cofactor 2                               | HEP2          | 6.47 | 57       | 3657        |
| 23        | Apolipoprotein D                                 | APOD          | 4.87 | 22       | 1762        |
| 24        | Dermcidin                                        | DCD           | 6.14 | 11       | 1472        |

**Table S5.** Protein abundancy for the Myocet protein corona from the centrifugation method determined with LFQ based on the TOP3 approach, analysed with the ISOQuant software.
Table S6. Background protein abundancy of the centrifugation method, determined with LFQ based on the TOP3 approach, analysed with the ISOQuant software.
| Abundance | Protein name                          | Protein entry | IEP | MW (kDa) | average ppm |
|-----------|--------------------------------------|---------------|-----|----------|-------------|
| 1         | Complement C3                        | CO3           | 5.99| 189      | 107751      |
| 2         | Inter-alpha-trypsin inhibitor heavy chain H2 | ITH2         | 6.43| 107      | 56604       |
| 3         | Inter-alpha-trypsin inhibitor heavy chain H1 | ITH1         | 6.35| 102      | 52182       |
| 4         | Kininogen-1                          | KNG1          | 6.38| 73       | 41911       |
| 5         | Inter-alpha-trypsin inhibitor heavy chain H3 | ITH3         | 5.39| 100      | 36208       |
| 6         | Serum albumin                        | ALBU          | 5.89| 71       | 36107       |
| 7         | Prothrombin                          | THR3          | 5.54| 72       | 36037       |
| 8         | Clusterin                            | CLUS          | 5.87| 53       | 30526       |
| 9         | Complement C4-B                      | CO4B          | 6.9 | 194      | 30066       |
| 10        | Serum paraoxonase/arylesterase 1     | PON1          | 4.93| 40       | 24734       |
| 11        | Alpha-2-macroglobulin                 | A2MG          | 6.04| 165      | 23372       |
| 12        | Ceruloplasmin                        | CERU          | 5.35| 123      | 20035       |
| 13        | Alpha-1-antitrypsin                  | A1AT          | 5.25| 47       | 19392       |
| 14        | Antithrombin-III                     | ANT3          | 6.33| 53       | 19378       |
| 15        | Gelsolin                             | GELS          | 5.87| 86       | 16063       |
| 16        | Hyaluronom-binding protein 2         | HABP2         | 6.11| 65       | 14756       |
| 17        | Apolipoprotein E                     | APOE          | 5.49| 36       | 14519       |
| 18        | Vitronectin                          | VTNC          | 5.45| 55       | 14243       |
| 19        | Immunoglobulin heavy constant mu     | IGHM          | 6.37| 50       | 13398       |
| 20        | Complement C1’s subcomponent         | C1S           | 4.66| 78       | 12534       |
| 21        | Complement C4-A                      | CO4A          | 6.68| 194      | 12532       |
| 22        | Plasma protease C1 inhibitor          | IC1           | 6.11| 55       | 12190       |
| 23        | Immunoglobulin heavy constant alpha 1 | IGHA1         | 6.09| 39       | 12126       |
| 24        | Inter-alpha-trypsin inhibitor heavy chain H4 | ITH4         | 6.56| 55       | 11681       |
| 25        | Heparin cofactor 2                   | HEP2          | 6.47| 57       | 11613       |
| 26        | Immunoglobulin heavy constant gamma 1 | IGHG1         | 8.2 | 37       | 11328       |
| 27        | Apolipoprotein A-I                   | APOA1         | 5.44| 31       | 10414       |
| 28        | Complement C1r subcomponent          | C1R           | 5.8 | 82       | 7903        |
| 29        | Complement C5                        | C5            | 6.11| 190      | 7690        |
| 30        | Holotranscobalamin-rich glycoprotein | HRG           | 7.13| 61       | 7685        |
| 31        | Protein AMBP                         | AMBP          | 5.9 | 40       | 7498        |
| 32        | Apolipoprotein A-I                   | APOA1         | 5.12| 45       | 7359        |
| 33        | Apolipoprotein F                     | APOF          | 5.31| 36       | 6835        |
| 34        | Vitamin K-dependent protein Z        | PROZ          | 5.59| 46       | 6812        |
| 35        | Lumican                              | LUM           | 6.19| 39       | 6654        |
| 36        | C-reactive protein                   | CRP           | 5.32| 25       | 6423        |
| 37        | Vitamin K-dependent protein C        | PROC          | 5.85| 53       | 6359        |
| 38        | Coagulation factor IX                | F9            | 5.19| 53       | 6183        |
| 39        | Complement component C9              | C9            | 5.28| 65       | 5813        |
| 40        | Beta-Aia-His dippeptidase             | CNDP1         | 4.98| 57       | 5729        |
| 41        | Vitamin K-dependent protein S        | PROS          | 5.35| 77       | 5542        |
| 42        | Alpha-2-antiplasmin                  | ASAP          | 5.87| 55       | 5530        |
| 43        | Apolipoprotein M                     | APOM          | 5.63| 22       | 5486        |
| 44        | Serotransferrin                      | TRFE          | 6.78| 79       | 4806        |
| 45        | Haptoglobin                          | HPT           | 6.15| 46       | 4769        |
| 46        | Thrombospondin-1                     | TSP1          | 4.53| 133      | 4166        |
| 47        | Coagulation factor X                 | FA10          | 5.59| 56       | 3870        |
| 48        | Alpha-1-antichymotrypsin             | AACT          | 5.19| 48       | 3725        |
| 49        | Immunoglobulin kappa constant        | IGKC          | 6.13| 12       | 3478        |
| 50        | Phosphatidylcholine-diacyltransferase | LCAT          | 5.69| 50       | 3298        |

**Table S7.** Protein abundancy for the EndoTAG-1 protein corona from the centrifugation method determined with LFQ based on the TOP3 approach, analysed with the ISOQuant software.
|   |   |   |
|---|---|---|
|51| Complement factor H| CFAH|
|52| Ficolin-3| FCN3|
|53| Apolipoprotein D| APOD|
|54| Angiotensinogen| ANG|
|55| Carbohydrate oligomeric matrix protein| COMP|
|56| Protein Z-dependent protease inhibitor| ZPI|
|57| Apolipoprotein A-II| APOA2|
|58| Galectin-3-binding protein| LGGBP|
|59| Lipoplysaccharide-binding protein| LBP|
|60| Endoplasm| ENFL|
|61| C4b-binding protein alpha chain| C4BPA|
|62| Secreted phosphoprotein 24| SPP24|
|63| Apolipoprotein C-II| APOC2|
|64| Thrombospondin-4| TSP4|
|65| Haptoglobin-related protein| HPT|
|66| Plasma serine protease inhibitor| IPSP|
|67| Apolipoprotein C-III| APOC3|
|68| Protease nexin II & alpha chain| GP1BA|
|69| Seltenprotein P| SEPP1|
|70| Membrane-binding lectin serine protease 1| MASPL|
|71| CDS antigen-like| CDSL|
|72| Apolipoprotein L1| APOL1|
|73| Complement C1q subcomponent subunit C| C1QC|
|74| SPARC-like protein 1| SPARC|
|75| Hemopexin| HEMO|
|76| Insulin-like growth factor-binding protein complex acid labile subunit| ALS|
|77| Immunoglobulin heavy constant gamma 3| IGHG3|
|78| Serum paraoxonase/lactonase 3| PON3|
|79| Transferrin| TF|
|80| Alpha-1B-glycoprotein| A1BG|
|81| Phosphatidylinositol-glycan-specific phospholipase D| PHLD|
|82| Immunoglobulin heavy constant alpha 2| IGHAA2|
|83| Immunoglobulin heavy constant gamma 2| IGHG2|
|84| Vitamin D-binding protein| VDBP|
|85| Alpha-2-HS-glycoprotein| FETUA|
|86| Complement C1q subcomponent subunit B| C1QB|
|87| Ferritin family homolog 3| FTH3|
|88| Complement component C3| C3|
|89| Complement factor B| CFB|
|90| Carboxypeptidase N subunit 2| CPN2|
|91| Phrenylethylamine oxidase| PCYX|
|92| C4b-binding protein beta chain| C4BPB|
|93| 14-3-3 protein zeta/delta| 143Z|
|94| Complement C1q subcomponent subunit A| C1QA|
|95| Pregnancy zone protein| PZP|
|96| Serum amyloid P-component| SAP|
|97| Lysozyme C| LYS|
|98| Kelatatin| KAN|
|99| Immunoglobulin heavy constant gamma 4| IGH4|
|100| Extracellular superoxide dismutase [Cu-Zn]| SOD2|
|101| Immunoglobulin J chain| IGJ|
|102| N-acetylmuramoyl-L-alanine amidase| PMRBP|
|103| Beta-2-glycoprotein 1| APOH|
|104| Retinal-binding protein 4| RET4|
|105| Zn-alpha-2-glycoprotein| ZAG|
|106| Hemoglobin subunit beta| HBB|
|107| Proteasome-inducible protein| PIP|
|108| Alpha-1-acid glycoprotein 2| AAG2|
|109| Desmin| DCD|
|110| Apolipoprotein C-IV| APOC4|
|111| Protein S100-A8| S10A8|
|112| Apolipoprotein C-I| APOC1|

**Table S7. Continued.**
Figure S8. Top 10 most abundant proteins in the corona determined by the centrifugation method for each formulation as well as the negative control in which buffer without liposomes was added to the serum. Complete abundancy lists can be found as table format in Tables S4-7.
Chemical Synthesis

General

All solvents and reagents were obtained from common commercial sources (Sigma Aldrich, Acros Organics, Alfa Aesar, Fluka, Merck) and used as received without further purification, unless stated otherwise. All reactions were performed under a nitrogen atmosphere, unless stated otherwise. Column chromatography was performed using silica gel (40-63 µm, 60 Å, Screening Devices, The Netherlands) or high purity silica gel (40-63 µm, 60 Å, Sigma-Aldrich). TLC analysis was performed on Merck silica gel 60/Kieselguhr F_{254}, 0.25 mm TLC plates. Compounds were visualized by UV adsorption or KMnO₄ stain (K₂CO₃ (15 g), KMnO₄ (2 g), and H₂O (200 mL)). ¹H, ¹³C and ³¹P NMR spectra were recorded on a Bruker AV 400 MHz or 850 MHz spectrometer. Chemical shifts are reported in ppm (δ), relative to the deuterated solvent as internal standard. Data are reported as follows: chemical shifts (δ), multiplicity (s = singlet, d = doublet, dd = doublet of doublet, t = triplet, q = quartet, br s = broad singlet, m = multiplet), coupling constants (J) reported in Hz. High resolution mass spectra were recorded by direct injection (2 µL of a 1 mM solution in methanol) using a mass spectrometer (Thermo Finnigan LTQ Orbitrap) with an electrospray ion source run in positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 250°C), and with a resolution R = 60,000 at m/z 400 (mass range m/z = 150-2,000) and dioctylphthalate (m/z = 391.28428) as a “lock mass”. The high-resolution mass spectrometer was calibrated prior to measurements with a calibration mixture (Thermo Finnigan). During the chemical synthesis of IKS02, no unexpected or unusually high safety hazards were encountered.
Chemical Procedures

Synthesis of diazirine and diacylglycerol building blocks

2-(3-methyl-3H-diazirin-3-yl)ethyl 4-methylbenzenesulfonate (1)

\[
\text{\begin{tikzpicture}
\draw[thick,black] (0.0,0.0) -- (0.5,0.5);
\draw[thick,black] (0.0,0.0) -- (0.5,-0.5);
\draw[thick,black] (0.0,0.0) -- (-0.5,0.0);
\draw[thick,black] (0.0,0.5) -- (0.5,0.0);
\draw[thick,black] (0.0,-0.5) -- (0.5,0.0);
\end{tikzpicture}}
\]

To 7N methanolic ammonia (11.2 mL, 79 mmol, 7 eq.) was added 4-hydroxybutan-2-one (0.98 mL, 11.35 mmol, 1 eq.) at 0 °C under nitrogen atmosphere. After stirring at 0 °C for 2.5 hours, the solution turned dark yellow. To the solution was added hydroxylamine-O-sulfonic acid (1.48 g, 13.05 mmol, 1.1 eq.) in methanol (9.7 mL) dropwise. The solution turned light yellow and was stirred overnight at room temperature until a white suspension was formed. The solid was filtered off and the ammonia was evaporated by gently blowing nitrogen through the solution. The solution was cooled down to 0 °C and to the solution was added triethylamine (1.6 mL, 11.35 mmol, 1 eq.), then was added in portions molecular iodine (±2 g) until the brown colour persisted. After 2 hours, the solution was quenched by the addition of brine (40 ml) and extracted with diethyl ether (3x). The organic layers were combined, washed with sodium thiosulfate (1x) and brine (1x). The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. To the crude was added pyridine (8 mL) and \( p \)-toluenesulfonylchloride (2.30 g, 12 mmol, 1.1 eq.). After stirring overnight at room temperature, the solution was poured onto ice (120 g). The solution was quenched with concentrated hydrogen chloride (10 mL), which was added dropwise. The mixture was extracted with diethyl ether (3x). The organic layers were combined and washed with saturated sodium bicarbonate (1x) and brine (1x). The collected organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. Flash column chromatography (silica gel, 8% ethyl acetate in petroleum ether) yielded 1 (640 mg, 2.50 mmol, 20%).
TLC: $R_f = 0.4$ (dichloromethane/methanol, 80:20 v/v). $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 7.81 (d, $J = 8.3$ Hz, 2H), 7.36 (d, $J = 8.0$ Hz, 2H), 3.94 (t, $J = 6.4$ Hz, 2H), 2.45 (s, 3H), 1.66 (t, $J = 6.4$ Hz, 2H), 0.99 (s, 3H). $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 145.17, 130.04, 128.08, 125.37, 65.23, 34.27, 23.50, 21.78, 19.88.

2-hydroxy-N,N-dimethyl-N-(2-(3-methyl-3H-diazirin-3-yl)ethyl)ethan-1-aminium (2)$^2$

\[ \text{HO-} \begin{array}{c} \text{N} \\ \text{N} \end{array} \text{N-} \begin{array}{c} \text{O} \\ \text{O} \\ \text{O} \end{array} \text{N-} \begin{array}{c} \text{O} \\ \text{O} \\ \text{O} \end{array} \]

To a solution of 1 (200 mg, 0.78 mmol, 1.1 eq.) in acetonitrile (700 μl) was added 2-dimethylaminoethanol (72 μl, 0.71 mmol, 1 eq.). After stirring overnight at 80 °C, additional 13 (10 mg, 0.039 mmol, 0.55 eq.) was added. After stirring overnight at 80 °C, the mixture was concentrated under reduced pressure to give the yellow/brown solid 2 (134 mg, 0.78 mmol, quant).

$^1$H NMR (400 MHz, MeOD) $\delta$ 7.71 (d, $J = 8.2$ Hz, 2H), 7.25 (d, $J = 8.0$ Hz, 2H), 4.02 – 3.89 (m, 2H), 3.50 – 3.44 (m, 2H), 3.43 – 3.40 (m, 2H), 3.13 – 3.09 (m, 4H), 2.38 (s, 3H), 1.88 – 1.80 (m, 2H), 1.07 (s, 2H). $^{13}$C NMR (100 MHz, MeOD) $\delta$ 143.62, 141.73, 129.87, 126.93, 66.43, 61.33, 56.81, 52.33, 52.29, 52.25, 29.28, 21.31, 19.35, 0.81.

Methyl 16-hydroxyhexadecanoate (3)

\[ \text{HO-} \begin{array}{c} \text{O} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{O} \end{array} \begin{array}{c} \text{O} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{O} \end{array} \]

To a solution of 16-hydroxyhexadecanoic acid (1.70 g, 6.6 mmol, 1 eq.) in methanol (100 mL) was added acetyl chloride (3.24 mL, 44.7 mmol, 8 eq.) at 0 °C. After stirring overnight, additional acetyl chloride (3 mL, 41.4 mmol) was added. Monitoring by TLC showed complete conversion after 2 hours. The mixture was then concentrated under reduced pressure and dissolved in dichloromethane. The solution was washed with a saturated sodium bicarbonate solution (2x), water (2x) and brine (1x). Every aqueous phase was extracted with dichloromethane (1x). The organic layers were combined,
dried over anhydrous sodium sulfate and evaporated under reduced pressure, yielding 3 as a white solid (1.73 g, 6.06 mmol, 92%).

\[ R_f = 0.8 \text{ (Pentanes/Ethyl acetate, 75:25 v/v)}. \]

\[ ^1H \text{ NMR (400 MHz, CDCl}_3\text{)} \delta 3.66 (s, 3H), 3.63 (t, J = 6.6 Hz, 2H), 2.30 (t, J = 7.6 Hz, 2H), 1.66 – 1.50 (m, 4H), 1.38 – 1.19 (m, 22H). \]

\[ ^{13}C \text{ NMR (100 MHz, CDCl}_3\text{)} \delta 63.24, 51.60, 34.26, 32.94, 29.77, 29.76, 29.74, 29.72, 29.57, 29.39, 29.29, 25.87, 25.17, 25.10 \]

**Methyl 16-azidohexadecanoate (4)**

![Methyl 16-azidohexadecanoate (4)](image)

To a solution of 3 (1.70 g, 6.06 mmol) and triethylamine (5.07 mL, 36.4 mmol, 6 eq.) in methanol (100 mL) was added methanesulfonyl chloride (1.88 mL, 24.2 mmol, 4 eq.) dropwise at 0 °C. After addition, the mixture was allowed to warm to room temperature and monitoring by TLC showed complete conversion of the starting materials after 3 hours. The mixture was concentrated under reduced pressure, dissolved in dichloromethane and the solution was washed with a saturated sodium bicarbonate solution (1x), water (1x) and brine (1x). The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure, yielding the mesylate intermediate which was taken to the next step without further purification.

To a solution of mesylate intermediate in N,N-dimethylformamide (40 mL) was added sodium azide (2.15 g, 33 mmol) and the solution was stirred at 70 °C for 2 hours. The mixture was concentrated under reduced pressure, dissolved in DCM and washed with water (3x), a saturated sodium bicarbonate solution (1x) and brine (1x). The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. Flash column chromatography (silica gel, 5-10% ethyl acetate in pentane) yielded 4 as a white solid (1.71 g, 5.51 mmol, 91%)
\[ R_f = 0.8 \text{ (Pentanes/Ethyl acetate, 75:15 v/v)}. \]

$^1$H NMR (400 MHz, CDCl3) δ 3.66 (s, 3H), 3.25 (t, \( J = 8 \text{ Hz, 2H} \)), 2.29 (t, \( J = 8 \text{ Hz, 2H} \)), 1.66 - 1.59 (m, 4H), 1.42 - 1.25 (m, 22H). $^{13}$C NMR (100 MHz, CDCl3) δ 174.43, 51.61, 51.56, 34.24, 29.75, 29.71, 29.66, 29.61, 29.57, 29.38, 29.38, 28.96

**16-Azidohexadecanoic acid (5)**

![16-Azidohexadecanoic acid](image)

To a solution of 4 (1.70 g, 5.49 mmol) in tetrahydrofuran and dioxane (1:1, 15 mL) was added a 4M NaOH solution (15 mL) and the reaction was stirred at room temperature overnight. The mixture was diluted with ethyl acetate (200 mL) and washed with a 1M HCl solution (2x), water (1x) and brine (1x). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure yielding 5 as a white solid (1.62 g, 5.21 mmol, 95%)

\[ R_f = 0.2 \text{ (Pentanes/Ethyl acetate, 75:25 v/v)}. \]

$^1$H NMR (400 MHz, CDCl3) δ 3.25 (t, \( J = 8 \text{ Hz, 2H} \)), 2.34 (t, \( J = 8 \text{ Hz, 2H} \)), 1.66 - 1.59 (m, 4H), 1.35 - 1.25 (m, 22H). $^{13}$C NMR (100 MHz, CDCl3) δ 180.53, 51.60, 29.74, 29.70, 29.66, 29.60, 29.55, 29.36, 29.28, 29.17, 28.95, 26.84, 24.78

**3-((tert-Butyldimethylsilyl)oxy)propane-1,2-diol (6)**

![3-((tert-Butyldimethylsilyl)oxy)propane-1,2-diol](image)

To a solution of tert-Butyldimethylsilyl chloride (1.0 gram, 6.6 mmol, 1 eq.) in dichloromethane (25 mL) was added dropwise a solution of glycerol (17.8 gram, 198.6 mmol, 30 eq.) and imidazole (1.35 gram, 19.8 mmol, 3 eq.) in dichloromethane (30 mL) and DMF (12 mL) at -18 °C. After stirring the solution for one hour at -18 °C, water (50 mL) was added. The resulting mixture was extracted with dichloromethane (3x). The organic layers were combined and washed with water (1x) and brine (1x), dried over anhydrous sodium sulfate and evaporated under reduced pressure. Flash column
chromatography (silica gel, 40% ethyl acetate in pentane) yielded 6 as a transparent oil (478 mg, 2.27 mmol, 34%).

\[ R_f = 0.54 \text{ (Pentane/Ethyl acetate, 50:50 v/v).} \]

1H NMR (400 MHz, CDCl3) \( \delta \) 3.81 – 3.55 (m, 5H), 0.90 (s, 9H), 0.08 (s, 6H). 13C NMR (100 MHz, CDCl3) \( \delta \) 71.71, 64.89, 64.35, 64.19, 25.98, 18.39, -5.34.

3-((tert-Butyldimethylsilyl)oxy)-2-hydroxypropyl propionate (7)

To a solution of stearic acid (295 mg, 1.04 mmol, 0.7 eq.) in dichloromethane (8 mL) were added N,N'-dicyclohexylcarbodiimide (257 mg, 1.04 mmol, 0.7 eq.) and 4-dimethylaminopyridine (90 mg, 0.74 mmol, 0.5 eq.). After stirring for 30 minutes at room temperature, the solution was cooled down to 0 °C. To the cooled solution was added 5 (310 mg, 1.48 mmol, 1 eq.). The solution was stirred at 0 °C for 30 min, allowed to warm up to room temperature and stirred overnight. The formed suspension was filtered and the filtrate was washed with saturated sodium bicarbonate solution (2x), water (2x) and brine (1x). The separate aqueous layers were extracted with dichloromethane (1x). The combined organic layers were dried over anhydrous sodium sulfate and evaporated under reduced pressure. Flash column chromatography (silica gel, 6% ethyl acetate in pentane), yielded 6 as a mixture of regioisomers (2°:1° = 7:43, determined by 1H-NMR) (374 mg, 0.790 mmol, 76%).

\[ R_f = 0.65 \text{ & 0.7 (Pentane/Ethyl acetate, 80:20 v/v).} \]

1H NMR (400 MHz, CDCl3) \( \delta \) 4.19 – 4.05 (m, 1H), 3.92 – 3.84 (m, 1H), 3.84 – 3.72 (m, 1H), 3.67 (dd, J = 10.1, 4.6 Hz, 1H), 3.60 (dd, J = 10.1, 5.6 Hz, 1H), 2.33 (t, J = 7.6 Hz, 2H), 1.70 – 1.55 (m, 2H), 1.25 (s, 28H), 0.94 – 0.77 (m, 12H), 0.07 (d, J = 2.6 Hz, 6H).

13C NMR (100 MHz, CDCl3) \( \delta \) 174.13, 74.38, 65.12, 63.81, 63.02, 62.70, 34.55, 34.34, 32.07, 29.84, 29.82, 29.80, 29.75, 29.61, 29.51, 29.42, 29.29, 25.97, 25.09, 22.84, 14.27, -5.33.
2-((16-Azidohexadecanoyl)oxy)-3-((tert-butyldimethylsilyl)oxy)propyl stearate (8)

To a solution of 5 (221 mg, 0.746 mmol, 1.05 eq.) in dichloromethane (8 mL), were added N,N'-dicyclohexylcarbodiimide (185 mg, 0.746 mmol, 1.05 eq.) and 4-dimethylaminopyridine (65 mg, 0.530 mmol, 0.75 eq.). After stirring for 30 minutes at room temperature, 7 was added (336 mg, 0.751 mmol, 1 eq.) and the solution was stirred overnight. The formed suspension was filtered and the organic phase was washed with saturated sodium bicarbonate solution (2x), water (2x) and brine (1x). The combined organic layers were dried over anhydrous sodium sulfate and evaporated under reduced pressure. Flash column chromatography (silica gel, 1.5% ethyl acetate in pentane) yielded 12 (340 mg, 0.452 mmol, 64%) as a mixture of regioisomers.

Rf = 0.3 (Pentane/Ethyl acetate, 95:5 v/v). \(^1\)H NMR (400 MHz, CDCl\(_3\)) \(\delta\) 5.17 – 4.95 (m, 1H), 4.33 (dd, J = 11.8, 3.7 Hz, 1H), 4.15 (dd, J = 11.8, 6.3 Hz, 1H), 3.79 – 3.54 (m, 2H), 3.25 (t, J = 7.0 Hz, 2H), 2.29 (dd, J = 7.9, 7.1, 2.1 Hz, 4H), 1.68 – 1.51 (m, 6H), 1.25 (s, 50H), 0.96 – 0.76 (m, 12H), 0.07 (s, 6H). \(^13\)C NMR (100 MHz, CDCl\(_3\)) \(\delta\) 173.61, 173.26, 71.80, 62.58, 61.58, 51.62, 34.49, 34.30, 32.07, 29.84, 29.81, 29.79, 29.77, 29.69, 29.63, 29.51, 29.44, 29.30, 29.27, 29.25, 28.98, 26.86, 25.08, 25.05, 22.83, 14.26, -5.36 (d, J = 4.2 Hz).

2-((16-Azidohexadecanoyl)oxy)-3-hydroxypropyl stearate (9)

To a solution of 8 (340 mg, 0.452 mmol, 1 eq.) in acetonitrile: tetrahydrofuran (1:1, 8 mL) was added triethylamine trihydrofluoride (0.74 mL, 4.52 mmol, 10 eq.). After stirring overnight at room temperature, the solution was quenched on ice with a saturated sodium bicarbonate solution. After
extraction with dichloromethane (4x), the organic layers were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. Flash column chromatography (silica gel, 20% ethyl acetate in pentane) yielded 9 (289 mg, 0.452 mmol, quant) as a mixture of regioisomers.

Rf = 0.8 (Pentane/Ethyl acetate, 80:20 v/v). $^1$H NMR (400 MHz, CDCl$_3$) δ 5.08 (p, J = 5.0 Hz, 1H), 4.32 (dd, J = 11.9, 5.6 Hz, 1H), 4.24 (dd, J = 11.9, 4.5 Hz, 1H), 4.21 – 4.13 (m, 1H), 3.75 – 3.71 (m, 1H), 3.25 (t, J = 7.0 Hz, 2H), 2.38 – 2.29 (m, 4H), 1.66 – 1.55 (m, 8H), 1.35 – 1.21 (m, 48H), 0.88 (t, J = 6.4 Hz, 3H).

$^{13}$C NMR (101 MHz, CDCl$_3$) δ 72.24, 62.11, 61.71, 51.64, 34.44, 34.26, 32.08, 29.85, 29.81, 29.79, 29.77, 29.69, 29.63, 29.52, 29.42, 29.40, 29.31, 29.27, 29.24, 28.99, 26.87, 25.09, 25.04, 22.85, 14.28.
**Phosphoramidite synthesis of IKS**

2-((16-Azidohexadecanoyl)oxy)-3-(((2-cyanoethoxy)(diisopropylamino)phosphanyl)oxy)propyl stearate (10)

A solution of 13 (200 mg, 0.313 mmol, 1 eq.) and diisopropylethylamine (329 μl, 1.88 mmol, 6 eq.) in dry dichloromethane (5 mL) was dried over freshly oven-dried 3Å molecular sieves and stored under nitrogen atmosphere. The mixture was transferred to a dry flask under nitrogen atmosphere and to the solution was added 2-cyanoethyl N,N-diisopropylchlorophosphoramide (250 mg, 1.056 mmol, 3 eq.). After stirring for 1.5 hours the solution was concentrated under reduced pressure until 600 mbar. Flash column chromatography, (high purity silica gel pre-treated with 5% triethylamine in pentane, 3% ethyl acetate and 3% Et₃N in pentane) yielded 16 (194 mg, 0.231 mmol, 74%). The product was stored in 20% triethylamine in dichloromethane (2 mL) under nitrogen atmosphere overnight. For the next reaction, the product was concentrated under reduced pressure until 60 mbar for maximum 10 minutes.

R<sub>f</sub> = 0.6 (Pentane/Ethyl acetate/Et₃N, 90:7:3 v/v/v)). ¹H NMR (400 MHz, CDCl₃) δ 4.29 – 4.06 (m, 2H), 3.92 – 3.72 (m, 2H), 3.67 – 3.54 (m, 1H), 3.25 (t, J = 7.0 Hz, 1H), 2.63 (td, J = 6.5, 2.3 Hz, 2H), 2.54 (q, J = 7.2 Hz, 4H), 2.30 (tt, J = 7.0, 3.5 Hz, 4H), 1.68 – 1.54 (m, 6H), 1.32 – 1.18 (m, 50H), 1.17 (q, J = 2.9 Hz, 12H), 0.87 (t, J = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.61, 69.68, 69.52, 64.03, 58.64, 58.46, 51.63, 46.38, 43.43, 43.31, 34.30 (d, J = 4.3 Hz), 32.07, 29.82 (d, J = 4.6 Hz), 29.66 (d, J = 5.9 Hz), 29.51, 29.45, 29.30, 28.98, 26.86, 25.03, 24.75, 24.65, 24.57, 22.83, 14.27, 11.69. ³¹P NMR (162 MHz, CDCl₃) δ 150.08, 149.50.
2-(((2-((16-Azidohexadecanoyl)oxy)-3-(stearoyloxy)propoxy)(2-cyanoethoxy)phosphoryl)oxy)-N,N-dimethyl-N-(2-(3-methyl-3H-diazirin-3-yl)ethyl)ethan-1-aminium (11)

A solution of 10 (194 mg, 0.231 mmol, 1 eq.) in dry dichloromethane (5 mL) was dried over freshly oven-dried 3Å molecular sieves under nitrogen atmosphere. To the solution were added 2 (79 mg, 0.231 mmol, 1 eq.) and tetrazole (1.03 mL, 0.462 mmol, 2 eq.). After stirring for 45 minutes, additional tetrazole (0.51 mL, 0.231 mmol, 1 eq.) and 15 (20 mg, 0.058 mmol, 0.25 eq.) were added. After 1 hour, \(^{31}\text{P-NMR}\) indicated complete conversion of the starting material (main peak shifted from 150 ppm to 140 ppm) to the solution was added tert-Butyl hydroperoxide (66 μL, 0.347 mmol, 1.5 eq.). After 45 minutes, \(^{31}\text{P-NMR}\) showed oxidation was complete (peak shifted from 140 ppm to -3 ppm), the solution was diluted with dichloromethane and washed with saturated sodium bicarbonate (1x) and brine (1x). The collected organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. Flash column chromatography (high purity silica gel, 10% methanol in dichloromethane) yielded 11 (20.5 mg, 5.54 μmol, 10%).

R<sub>f</sub> = 0.3 (dichloromethane/methanol, 80:20 v/v), \(^1\text{H NMR}\) (400 MHz, CDCl<sub>3</sub>) δ 4.88 – 4.63 (m, 2H), 4.50 – 4.31 (m, 3H), 4.27 – 4.12 (m, 4H), 3.65 (d, J = 5.4 Hz, 2H), 3.40 (s, 6H), 3.25 (t, J = 7.0 Hz, 2H), 3.11 (qd, J = 7.3, 4.8 Hz, 4H), 2.90 (s, 2H), 2.43 – 2.26 (m, 4H), 1.90 (s, 2H), 1.65 – 1.52 (m, 6H), 1.25 (s, 50H), 1.17 (s, 3H), 0.87 (t, J = 6.7 Hz, 3H). \(^{31}\text{P NMR}\) (162 MHz, CDCl<sub>3</sub>) δ -2.68, -3.33. ESI-HRMS (m/z) C<sub>48</sub>H<sub>91</sub>N<sub>7</sub>O<sub>8</sub>P<sup>+</sup>: [M]<sup>+</sup> calculated: 925.27, found: 923.98.
2-((16-Azidohexadecanoyl)oxy)-3-(stearoyloxy)propyl (2-(dimethyl(2-(3-methyl-3H-diazirin-3-yl)ethyl)ammonio)ethyl) phosphate (IKS02)

To a solution of 17 (10.26 mg, 11.08 μmol) in dry dichloromethane (3 mL) was added a mixture of tert-butylamine and dichloromethane (1:1, 100 μL) and the mixture was stirred at room temperature for 3 hours. The solution was concentrated under reduced pressure. The product was purified with column chromatography (high purity silica gel, 17% methanol in dichloromethane) and yielded IKS02 as a white solid (5.66 mg, 5.32 μmol, 48%).

Rf = 0.3 (dichloromethane/methanol, 70:30 v/v). $^1$H NMR (850 MHz, CDCl$_3$) δ 4.55 (s, 1H), 4.40 (s, 3H), 4.27 (dd, J = 11.7, 5.3 Hz, 2H), 4.24 (dd, J = 11.5, 4.6 Hz, 2H), 4.01 (s, 1H), 3.86 (s, 2H), 3.58 (t, J = 8.4 Hz, 2H), 3.30 (s, 6H), 3.25 (t, J = 7.0 Hz, 2H), 2.31 (t, J = 7.7 Hz, 6H), 1.87 (q, J = 8.8 Hz, 2H), 1.59 (h, J = 7.1 Hz, 6H), 1.33 – 1.18 (m, 48H), 1.15 (s, 3H), 0.88 (t, J = 7.1 Hz, 3H). $^{31}$P NMR (162 MHz, CDCl$_3$) δ -1.82. ESI-HRMS (m/z) C$_{45}$H$_{87}$N$_6$O$_8$P: [M]+ calculated: 871.1780, found: 871.63958.
Biological Methods & Proteomics

General

All solvents and reagents were obtained from common commercial sources (Sigma Aldrich, Acros Organics, Alfa Aesar, Fluka, Merck) and used without further purification, unless stated otherwise. Dynamic light scattering and zeta potential measurements were performed on a Malvern Zetasizer Nano ZS. For light irradiation, a CaproBox™ (Caprotec Bioanalytics GmbH) was used with a wavelength of 350 nm and applying a 300 nm light filter. Human serum was purchased from Sigma-Aldrich (Non Heat Inactivated, Human Male AB plasma, USA origin, sterile-filtered, product code: H4522) with a protein concentration of 60.2 µg/µl determined by a Pierce BCA Protein Assay Kit (Thermo Scientific). The serum was aliquoted, snap-frozen with liquid nitrogen and stored for a maximum of 6 months at -80 °C. Albumin from human serum (SRP6182), Human transferrin (T3309) and recombinant human apolipoprotein E3 (SRP4696) were purchased from Sigma-Aldrich. Human prothrombin (RP-43087) was purchased from Thermo-Fisher Scientific. Recombinant human Apolipoprotein A1 (ab50239) was purchased from Abcam B.V. (Amsterdam, The Netherlands).

Evaporation of solvents with a vacuum centrifuge was performed using an Eppendorf speedvac (Eppendorf Concentrator Plus 5301). Sequencing grade modified trypsin was purchased from Promega (product code = V5111). Acetonitrile (LC-MS grade) and methanol (LC-MS grade) were purchased from Biosolve. Formic acid (LC-MS grade) was purchased from Actu-All Chemicals. BioSpin columns were purchased from Bo-Rad. The Empore C18 47-mm extraction disks (model 2215) were purchased from 3M™ Purification. Enolase digest standard was purchased from Waters MassPREP™.

Throughout the biological and proteomic methods, no unexpected or unusually high safety hazards were encountered.
Biological and Proteomic Procedures

Liposome preparation

Lipids were combined from stock solutions (10 mM in CHCl₃:MeOH 1:1 v/v) at the desired molar ratios. The solvents were evaporated under a nitrogen flow and traces of solvents were removed in vacuo for at least 30 minutes. Lipid films were hydrated with the desired volume of 20 mM HEPES (pH 7.4), vortexed and warmed to 65 °C for 5 minutes. The mixture was extruded thirteen times through two stacked 100 nm polycarbonate membranes (Nucleopore Track-Etch, Whatman) using an Avanti Mini Extruder (Avanti Polar Lipids). Size and surface charge were measured by Dynamic Light Scattering (DLS) and Zeta Potential measurement and liposomes were stored in the dark at 4 °C for no longer than two weeks.

Photoaffinity method

Incubation, crosslinking and click chemistry

Liposomes containing the photoaffinity probe (25 μL, 5 mM) were added to pre-warmed human serum (37 °C, 25 μL, 60.26 mg/ml protein) and incubated in the dark at 37 °C for 1 hour. For every liposome formulation, twelve replicates were prepared. Half of the replicates were irradiated with 350 nm light for 15 minutes, while cooling. The other replicates were kept at room temperature in the dark for 15 minutes. Afterwards, the liposomes were solubilized by addition of 10 μL 0.2% Triton X-100 in ultrapure water and incubation for 30 minutes. The samples were diluted by adding 140 μL of 0.1% SDS in ultrapure water. Aliquots of 100 μL were taken and protein precipitation was performed according to Wessel and Flügge. Briefly, ultrapure water (400 μL), methanol (650 μL), chloroform (200 μL) and ultrapure water (150 μL) were added sequentially, followed by vigorous vortexing and centrifugation (3000 g, 10 min, rt). The liquid layers were removed, the pellet resuspended with methanol (600 μL) and centrifuged (14,000 g, 5 min, rt). The supernatant was discarded and the pellet was dissolved in HEPES buffer containing 0.5% SDS (200 μL, 100 mM, pH 8.0).
A BCA assay was performed to determine the protein concentration and the samples were diluted to a volume of 450 μL with HEPES buffer with 0.5% SDS (100 mM, pH 8.0) with a protein concentration of 0.5-1.0 mg/mL. For each protein sample, click reagent mixture (50 μL) was added from a 10x concentrated stock to give a final concentration of 100 μM CuSO₄, 1000 μM sodium ascorbate, 500 μM THPTA, 5000 μM aminoguanidine and 20 μM Cy5-alkyne or Biotin-alkyne, followed by incubation at room temperature for 1 hour. Methanol (650 μL), chloroform (150 μL) and ultrapure water (150 μL) were added sequentially, the mixture vortexed and centrifuged (3000 g, 10 min, rt). The liquid layers were removed, resuspended with methanol (600 μL) and centrifuged (14,000 g, 5 min, rt). The pellet was air-dried at room temperature for 5-10 minutes and resuspended in freshly prepared denaturing buffer (250 μL, 6 M urea, 25 mM NH₄HCO₃) and used for in-gel fluorescence imaging or enrichment. Alternatively, samples were snap-frozen with liquid nitrogen and stored for no longer than 2 weeks at -80 °C.

**SDS-Page and in-gel fluorescence imaging**

Protein concentration was determined by BCA assay prior to loading samples for in-gel fluorescence. To a volume corresponding to 10 μg of protein was added Laemmli buffer (4x stock) and the proteins were resolved on a 12.5% PA gel at 180 V. The subset of fluorescent proteins was imaged on a Typhoon FLA 9500 (GE Healthcare), followed by staining of all the proteins with Coomassie Brilliant Blue R-250 staining solution (Bio-Rad) and imaging on a ChemiDoc MP system (Bio-Rad).

**Reduction and alkylation**

To lipid-protein samples conjugated to biotin, 5 μL (1 M DTT; 20 mM final concentration) was added. Samples were vortexed, centrifuged and incubated at 56 °C while shaking (600 rpm) for 30 minutes. The samples were allowed to cool down to room temperature, after which 40 μl 0.5 M iodoacetamide (80 mM final concentration) was added and the samples incubated at room temperature in the dark for 30 minutes. Afterwards, 20 μL 1 M DTT (100 mM final concentration) was added and the samples...
were vortexed and incubated at 56 °C for 5 minutes. Reduced and alkylated proteins were used directly for avidin bead enrichment.

**Enrichment and on-bead digestion**

Avidin agarose beads (50% slurry, 100 μL per sample, Thermo Fisher Scientific) were washed three times with PBS (10 mL PBS per 400 μL slurry), centrifuging at 2500 g for 3 minutes. The beads were resuspended in PBS (1 mL PBS per 100 μL slurry) and divided over 15 mL tubes in 1 mL fractions. An additional 2 mL PBS was added to each tube, after which the denatured and alkylated protein samples were added and the samples were shaken gently in an overhead shaker at RT for at least 3 hours. Beads were pelleted (2,500 g, 5 min) and the supernatant discarded. The beads were washed twice with SDS in PBS (0.5% w/v, 10 mL), three times with PBS (10 mL) and twice with ultrapure water (10 mL). In between each washing step, the samples were vortexed, centrifuged (2,500 g, 5 min) and the supernatants were discarded. The washed beads were resuspended in 250 μL on-bead digestion buffer (100 mM TRIS pH 8.0, 100 mM NaCl, 1 mM CaCl₂ and 2% v/v acetonitrile (LC-MS grade)) and transferred to 1.5 mL low-binding Eppendorf tubes, after which 10 μL 0.1 μg/μL trypsin was added and the samples were incubated at 37 °C while shaking (950 rpm) overnight. To the samples was added 12.5 μL formic acid, after which they were loaded onto Bio-Spin columns (Bio-Rad) and the flow-through was collected by centrifugation (2,500 g, 2 min) in low-binding Eppendorf tubes. The samples were desalted using the StageTips procedure described below.

**Protein binding validation experiment**

Human serum albumin (ALBU, 25 μg), transferrin (TRFE, 10 μg), apolipoprotein A1 (APOA1, 2 μg), apolipoprotein E3 (APOE, 2 μg) and prothrombin (THRB, 2 μg) were mixed in a total volume of 17.5 μL (PBS) for each replicate. To each replicate was added liposomes containing IKS02 (7.5 μL, 5 mM). For competition experiments, liposomes without IKS02 added were according to the competitive ratio (5 mM, 1:1 = 7.5 μL, 1:4 = 30 μL, 1:9 = 67.5 μL). The mixture was incubated at 37 °C for 1 hour followed
by liposome solubilisation with 1% Triton X-100 (5 μL). Proteins were precipitated by addition of ultrapure water, up to a volume of 100 μL, methanol (100 μL) and chloroform (50 μL), followed by vigorous vortexing and centrifugation (3000 g, 10 min, rt). The liquid layers were removed, the pellet resuspended with methanol (200 μL) and centrifuged (14,000 g, 5 min, rt). The supernatant was discarded and the pellet was dissolved in HEPES buffer (45 μL, 100 mM, pH 8.0). For each protein sample, click reagent mixture (5 μL) was added from a 10x concentrated stock to give a final concentration of 100 μM CuSO4, 1000 μM sodium ascorbate, 500 μM THPTA, 5000 μM aminoguanidine and 20 μM Cy5-alkyne or Biotin-alkyne, followed by incubation at room temperature for 1 hour. Protein precipitation was repeated as prior to the click reaction and the pellet was dissolved in PBS (50 μL) from which an aliquot was taken to perform a BCA assay. For in-gel fluorescence measurement, aliquots containing 10 μg protein were analysed by SDS-PAGE and in-gel fluorescence as described before. For MS/MS experiments, aliquots containing 20 μg protein were taken for reduction and alkylation and further steps as described before.

Centrifugation method

Centrifugation, washing and SDS-PAGE

The centrifugation method for protein corona determination was performed as previously described.5–7 Briefly, human serum (100 μL, 60.26 μg/μL protein) was thawed on ice and warmed to 37 °C prior to incubation with liposomes (100 μL, 1 mg/mL) at 37 °C in low-binding Eppendorf tubes for one hour. The samples were centrifuged (17,500 g, 15 min) and the supernatant was discarded. The pellets were washed by dissolving in PBS (100 μL, pH 7.4) and centrifugation (17,500 g, 15 min). This washing step was performed two more times, after which the pellets were dissolved in 1% SDS containing Laemmli buffer (20 μL), denatured at 95 °C for 5 minutes and resolved on a 12.5% poly acrylamide gel. The gel was fixed and stained using Coomassie Brilliant Blue R-250 staining solution,
imaged on a ChemiDoc MP system (Bio-Rad) followed by in-gel reduction, alkylation and digestion as described below.

**In-gel reduction, alkylation and digestion**

The SDS-PAGE gel lanes were cut in pieces of approximately 3 mm and transferred to 1.5 mL low-binding Eppendorf tubes. The gel pieces were washed with 25 mM NH₄HCO₃/acetonitrile (95:5, v/v) (400 μL) for 30 minutes and twice with 50 mM NH₄HCO₃/acetonitrile (50:50 v/v, 400 μL) for 30 minutes. The gel pieces were dehydrated by the addition of acetonitrile (300 μL, 10 min), after which the liquids were removed and the gel pieces were dried with a vacuum centrifuge. The gel pieces were hydrated with a 10 mM DTT in 100 mM NH₄HCO₃ solution (200 μL) and incubated at 56 °C for 1 hr. The excess liquid was removed, 55 mM IAA in 100 mM NH₄HCO₃ (200 μL) added and the solution incubated at room temperature in the dark for 45 minutes. The gel pieces were subsequently washed with 100 mM NH₄HCO₃ (200 μL) for 10 minutes and acetonitrile (200 μL) for 10 minutes. These washing steps were repeated two more times and the pieces were dried with a vacuum centrifuge.

The gel pieces were hydrated with digestion buffer (200 μL, 5 ng/μL trypsin in 50 mM NH₄HCO₃/acetonitrile 90:10 v/v) and incubated at 37 °C overnight. Formic acid in 50 mM NH₄HCO₃ (100 μL, 5:95 v/v) was added and the supernatants of the corresponding gel lanes were combined. To the gel pieces was added a solution of acetonitrile/50 mM NH₄HCO₃/formic acid (50:45:5 v/v, 100 μL) followed by incubation at room temperature for 45 minutes. The gel pieces were sonicated for 5 minutes and the supernatants were combined with the previous supernatants of the corresponding gel lanes. This last extraction step was performed one more time. Finally, a solution of acetonitrile/50 mM NH₄HCO₃/formic acid (90:5:5 v/v, 100 μL) was added and incubated at room temperature for 5 minutes. The supernatants were combined and dried using a vacuum centrifuge. The protein digests were dissolved in 100 μL StageTip solution A (0.5% (v/v) formic acid in ultrapure water) and desalted, using the StageTip procedure described below, before analysis by UPLC MS/MS.
**In-solution reduction, alkylation and digestion**

Six aliquots of human serum (20 μL, 60.26 mg/ml protein) were precipitated according to Wessel and Flügge. Briefly, ultrapure water (480 μL), methanol (650 μL), chloroform (200 μL) and ultrapure water (150 μL) were added sequentially, followed by vigorous vortexing and centrifugation (3000 g, 10 min, RT). The liquid layers were removed, the pellet resuspended with methanol (600 μL) and centrifuged (14,000 g, 5 min, RT). The supernatant was discarded and the pellet was dissolved in freshly prepared denaturing buffer (250 μL, 6M Urea and 25 mM NaHCO₃). A BCA assay was performed to determine the protein concentration and aliquots were taken corresponding to 100 μg of protein, followed by dilution to 100 μL with denaturing buffer. To the sample was added 5 μL 0.2 M DTT and the sample was incubated at 56 °C for 30 minutes, followed by the addition of 25 μL 0.2 M Iodoacetamide and incubation at room temperature for 30 minutes. An additional 20 μL 0.2 M DTT was added and the sample was incubated at 56 °C for 5 minutes. Aliquots of 22.5 μL (15 μg of protein) were transferred to low-binding Eppendorf tubes and diluted to 200 μL with digestion buffer (100 mM TRIS pH 8.0, 100 mM NaCl, 1 mM CaCl₂ and 2% v/v acetonitrile (LC-MS grade)), to reduce the urea concentration to ~0.6 M, after which 3 μL, 0.1 μg/μL trypsin (1:50 w/w trypsin:protein) was added and the samples were incubated at 37 °C while shaking (950 rpm) overnight. After digestion, 10 μL formic acid was added and the samples were desalted using the StageTip procedure described below.

**StageTip desalting**

The protein digest desalting procedure was conducted as previously described. Briefly, C₁₈ extraction disks (47 mm) were placed in 200 μL pipette tips. These StageTips were conditioned, loaded, washed and eluted, following the scheme below. The eluted fractions were collected into low-binding Eppendorf tubes, dried using a vacuum centrifuge and stored at -20 °C or immediately prepared for UPLC-MS/MS measurements.
STAGE | BUFFER
--- | ---
Conditioning 1 | 50 μL MeOH (LC-MS grade)
Conditioning 2 | 50 μL StageTip solution B: 0.5% (v/v) formic acid, 80% (v/v) acetonitrile and 19.5% ultrapure water
Conditioning 3 | 50 μL StageTip solution A: 0.5% (v/v) formic acid in ultrapure water
Loading | Sample
Washing | 100 μL StageTip solution A
Elution | 100 μL StageTip solution B

**NanoUPLC-MS/MS analysis**

LC-MS was performed as described previously.\(^9\) Peptide samples were dissolved in 50 μL LC-MS sample solution (ultrapure water:acetonitrile:formic acid 97:3:0.1) containing 10 fmol/μL enolase digest as an internal standard for label-free quantification. DMSO was not added to the LC solvents. Instead, a lower source temperature (80 °C instead of 100 °C) was used. A trap–elute protocol was used, in which a digest is loaded on a trap column and eluted and separated on the analytical column. The samples were brought on this trap column at a flow rate of 10 μl/min with 99.5% solvent A for 2 min, after which the column was switched to the analytical column. The peptide separation was achieved using a multistep concave gradient based on the gradients described elsewhere.\(^10\) After washing with 90% solvent B, the column was re-equilibrated to initial conditions.

The detailed protocol is specified below:

| TIME (MIN) | GRADIENT (%B) | COMPOSITION (%) | FLOW RATE (NL/MIN) |
|------------|---------------|-----------------|--------------------|
| 0          | 1.0           |                 | 300                |
| 2.4        | 1.0           |                 | 300                |
| 4.2        | 5.0           |                 | 300                |
| 10.2       | 7.6           |                 | 300                |
The rear seals of the pump were flushed every 30 min with 10% (v/v) ACN. [Glu1]-fibrinopeptide B (GluFib) was used as a lock mass compound. The auxiliary pump of the LC system was used to deliver this peptide to the reference sprayer (0.2 μl/min). As MS acquisition method, UDMS\textsuperscript{e} method was set up as described previously.\textsuperscript{10} Briefly, these settings include that the mass range was set from 50 to 2,000 Da, with a scan time of 0.6 s in positive resolution mode. To be able to use the low-energy MS mode, the collision energy was set to 4 V in the trap cell. Besides, the transfer cell collision energy was ramped using drift-time-specific collision energies for the elevated energy scan\textsuperscript{11}. The lock mass was sampled every 30 s.

**MS acquisition method**

The Synapt G2Si mass spectrometer (Waters) operating with Masslynx for acquisition and PLGS for peptide identification was used for analysis. The following settings in positive resolution mode were
used: source temperature of 80°C, capillary voltage 3.0 kV, nano flow gas of 0.25 Bar, purge gas 250 L/h, trap gas flow 2.0 ml/min, cone gas 100 L/h, sampling cone 25V, source offset 25, lock mass acquiring was done with a mixture of Leu Enk (556.2771) and Glu Fib (785.84265), lock spray voltage 2.5 kV, Glufib fragmentation was used as calibrant. An UDMS⁺ data-independent acquisition method was used for analysis. Briefly, the mass range is set from 50 to 2,000 Da with a scan time of 0.6 seconds in positive, resolution mode. The collision energy is set to 4 V in the trap cell for low-energy MS mode. For the elevated energy scan, the transfer cell collision energy is ramped to higher collision energies and data is recorded. The lock mass was sampled every 30 seconds and used for accurate determination of parent ions mass after peak picking. The PLGS search engine was used for peptide identification against the Uniprot human database to which the streptavidin, avidin, yeast enolase and trypsin sequences were manually added. The ISOQuant software¹⁰ was used for label free quantification of proteins using 50 fmol of yeast enolase digest as benchmark.

Proteomic analysis

Configuration parameters for label-free quantification (LFQ) in the ISOQuant software are listed in Supplementary Table 2. For quantification, +UV and –UV replicates for all samples were compared in separate groups. The protein lists were filtered by excluding proteins that are considered as contamination (e.g. keratins), non-endogenous (e.g. trypsin, avidin) or non-reproducible (not present in six out of six +UV or centrifugation samples). For the volcano plots, the ratio of average ppm for each protein was calculated and is displayed as a logarithmic value (log₂). Furthermore, the p-value was determined by multiple t-tests comparing the replicates of each group using the GraphPad Prism software. In addition, a Benjamini-Hochberg correction was applied to adjust the p-value for multiple comparisons. The final adjusted p-value is displayed as a logarithmic value (log₁₀). Proteins that were exclusive for +UV samples or did not occur more than once in the –UV samples, making a t-test impossible, were labelled as ‘exclusive’ and are listed next to the volcano plot. Abundance plots were generated by plotting the ppm values of all six replicates. Similar statistical analysis was performed for
validation experiments, with slight modifications: (1) the number of replicates here was four, but proteins still had to be present in four out of four replicates. (2) A Benjamini-Hochberg correction was no longer performed as the processing did not require a high amount of comparisons for the t-test. Instead, p-values were directly taken from t-tests and displayed as the logarithmic value ($10^{\log}$).

Absolute quantification was achieved from the same LFQ in ISOQuant, based on a comparison to the internal standard (ENLS digest, 50 fmol). The proteins that passed the criteria for the volcano plots were selected. The average absolute amount of these proteins in the +UV samples was corrected for the average in the –UV samples. For heat map construction, the sum of ppm values for all ‘accepted’ proteins within the sample was taken and the relative abundance of every protein was calculated as a ratio expressed in percentages of this value. For the photoaffinity method, the proteins within the enrichment and p-value boundaries of the volcano plot were considered as ‘accepted’. For the centrifugation method, all besides the initially filtered proteins were considered as ‘accepted’. Fully processed proteomic data for all samples is provided in two separate excel spreadsheets.

The mass spectrometry proteomics data have also been deposited to the ProteomeXchange Consortium via the PRIDE$^{12}$ partner repository with the dataset identifier PXD016229.
References

(1) Bulbake, U.; Doppalapudi, S.; Kommineni, N.; Khan, W. Liposomal Formulations in Clinical Use: An Updated Review. *Pharmaceutics* 2017, 9, 12.

(2) Shen, K.; Logan, A. W. J.; Colell, J. F. P.; Bae, J.; Ortiz, G. X.; Theis, T.; Warren, W. S.; Malcolmson, S. J.; Wang, Q. Diazirines as Potential Molecular Imaging Tags: Probing the Requirements for Efficient and Long-Lived SABRE-Induced Hyperpolarization. *Angew. Chemie Int. Ed.* 2017, 56, 12112–12116.

(3) Heal, W. P.; Jovanovic, B.; Bessin, S.; Wright, M. H.; Magee, A. I.; Tate, E. W. Bioorthogonal Chemical Tagging of Protein Cholesterylization in Living Cells. *Chem. Commun.* 2011, 47, 4081–4083.

(4) Wessel, D.; Flügge, U. I. A Method for the Quantitative Recovery of Protein in Dilute Solution in the Presence of Detergents and Lipids. *Anal. Biochem.* 1984, 138, 141–143.

(5) Bigdeli, A.; Palchetti, S.; Pozzi, D.; Hormozi-Nezhad, M. R.; Baldelli Bombelli, F.; Caracciolo, G.; Mahmoudi, M. Exploring Cellular Interactions of Liposomes Using Protein Corona Fingerprints and Physicochemical Properties. *ACS Nano* 2016, 10, 3723–3737.

(6) Capriotti, A. L.; Caracciolo, G.; Caruso, G.; Cavaliere, C.; Pozzi, D.; Samperi, R.; Laganà, A. Analysis of Plasma Protein Adsorption onto DC-Chol-DOPE Cationic Liposomes by HPLC-CHIP Coupled to a Q-TOF Mass Spectrometer. *Anal. Bioanal. Chem.* 2010, 398, 2895–2903.

(7) Barrán-Berdón, A. L.; Pozzi, D.; Caracciolo, G.; Capriotti, A. L.; Caruso, G.; Cavaliere, C.; Riccioli, A.; Palchetti, S.; Laganà, A. Time Evolution of Nanoparticle-Protein Corona in Human Plasma: Relevance for Targeted Drug Delivery. *Langmuir* 2013, 29, 6485–6494.

(8) Rappsilber, J.; Mann, M.; Ishihama, Y. Protocol for Micro-Purification, Enrichment, Pre-Fractionation and Storage of Peptides for Proteomics Using StageTips. *Nat. Protoc.* 2007, 2,
van Rooden, E. J.; Florea, B. I.; Deng, H.; Baggelaar, M. P.; Zhou, J.; Overkleeft, H. S.; van der Stelt, M. Mapping in Vivo Target Interaction Profiles of Covalent Inhibitors Using Chemical Proteomics with Label-Free Quantification. *Nat. Protoc.* 2018, 13, 752–767.

Distler, U.; Kuharev, J.; Navarro, P.; Tenzer, S. Label-Free Quantification in Ion Mobility-Enhanced Data-Independent Acquisition Proteomics. *Nat. Protoc.* 2016, 11, 795–812.

Distler, U.; Kuharev, J.; Navarro, P.; Levin, Y.; Schild, H.; Tenzer, S. Drift Time-Specific Collision Energies Enable Deep-Coverage Data-Independent Acquisition Proteomics. *Nat. Methods* 2014, 11, 167–170.

Vizcaíno, J. A.; Côté, R. G.; Csordas, A.; Dianes, J. A.; Fabregat, A.; Foster, J. M.; Griss, J.; Alpi, E.; Birim, M.; Contell, J.; et al. The Proteomics Identifications (PRIDE) Database and Associated Tools: Status in 2013. *Nucleic Acids Res.* 2012, 41, D1063–D1069.
Exact Mass: 871.64

C_{40}H_{77}N_2O_4 P + H:
C_{40}H_{78}N_2O_4 P_1
p (398.5040) C rel 1
R (50000 Res. Per. @ FWHM)